Mark Leschly - Net Worth and Insider Trading

Mark Leschly Net Worth

The estimated net worth of Mark Leschly is at least $0 dollars as of 2024-11-06. Mark Leschly is the Director of Anacor Pharmaceuticals Inc and owns about 0 shares of Anacor Pharmaceuticals Inc (ANAC) stock worth over $0. Mark Leschly is also the Director of Senomyx Inc and owns about 0 shares of Senomyx Inc (SNMX) stock worth over $0. Details can be seen in Mark Leschly's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Mark Leschly has not made any transactions after 2014-08-27 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Mark Leschly

To

Mark Leschly Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Mark Leschly owns 12 companies in total, including NGM Biopharmaceuticals Inc (NGM) , Cara Therapeutics Inc (CARA) , and IntraLinks Holdings Inc (IL) among others .

Click here to see the complete history of Mark Leschly’s form 4 insider trades.

Insider Ownership Summary of Mark Leschly

Ticker Comapny Transaction Date Type of Owner
NGM NGM Biopharmaceuticals Inc 2019-04-03 director
CARA Cara Therapeutics Inc 2016-03-16 10 percent owner
IL IntraLinks Holdings Inc 2017-01-19 10 percent owner
LIMIT LIMIT 2016-12-03 10 percent owner
LIMIT LIMIT 2016-06-24 director
LIMIT LIMIT 2015-02-17 10 percent owner
LIMIT LIMIT 2015-01-02 10 percent owner
LIMIT LIMIT 2012-11-28 10 percent owner
LIMIT LIMIT 2007-05-31 director
LIMIT LIMIT 2006-11-06 10 percent owner
LIMIT LIMIT 2021-02-02 10 percent owner
LIMIT LIMIT 2021-02-26 director

Mark Leschly Latest Holdings Summary

Mark Leschly currently owns a total of 2 stocks. Among these stocks, Mark Leschly owns 0 shares of Anacor Pharmaceuticals Inc (ANAC) as of August 27, 2014, with a value of $0 . Mark Leschly also owns 0 shares of Senomyx Inc (SNMX) as of November 2, 2006, with a value of $0 .

Latest Holdings of Mark Leschly

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ANAC Anacor Pharmaceuticals Inc 2014-08-27 0 9.82 0
SNMX Senomyx Inc 2006-11-02 0 1.49 0

Holding Weightings of Mark Leschly


Mark Leschly Form 4 Trading Tracker

According to the SEC Form 4 filings, Mark Leschly has made a total of 0 transactions in Anacor Pharmaceuticals Inc (ANAC) over the past 5 years. The most-recent trade in Anacor Pharmaceuticals Inc is the sale of 13,067 shares on August 27, 2014, which brought Mark Leschly around $294,008.

According to the SEC Form 4 filings, Mark Leschly has made a total of 0 transactions in Senomyx Inc (SNMX) over the past 5 years. The most-recent trade in Senomyx Inc is the sale of 17,875 shares on November 2, 2006, which brought Mark Leschly around $270,270.

Insider Trading History of Mark Leschly

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Mark Leschly Trading Performance

GuruFocus tracks the stock performance after each of Mark Leschly's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mark Leschly is 53.41%. GuruFocus also compares Mark Leschly's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mark Leschly within 3 months outperforms 2 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Mark Leschly's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Mark Leschly

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
2 out of 2 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 5.4 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 4.25 LIMIT LIMIT LIMIT LIMIT LIMIT

Mark Leschly Ownership Network

Ownership Network List of Mark Leschly

No Data

Ownership Network Relation of Mark Leschly

Insider Network Chart

Mark Leschly Owned Company Details

What does NGM Biopharmaceuticals Inc do?

Who are the key executives at NGM Biopharmaceuticals Inc?

Mark Leschly is the director of NGM Biopharmaceuticals Inc. Other key executives at NGM Biopharmaceuticals Inc include director & 10 percent owner David V Goeddel , 10 percent owner Column Group L P , and Chief Financial Officer Jean-frederic Viret .

NGM Biopharmaceuticals Inc (NGM) Insider Trades Summary

Over the past 18 months, Mark Leschly made no insider transaction in NGM Biopharmaceuticals Inc (NGM). Other recent insider transactions involving NGM Biopharmaceuticals Inc (NGM) include a net purchase of 67,893 shares made by Column Group L P , and a net purchase of 26,811 shares made by David V Goeddel .

In summary, during the past 3 months, insiders sold 0 shares of NGM Biopharmaceuticals Inc (NGM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of NGM Biopharmaceuticals Inc (NGM) were sold and 94,704 shares were bought by its insiders, resulting in a net purchase of 94,704 shares.

NGM Biopharmaceuticals Inc (NGM)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

NGM Biopharmaceuticals Inc Insider Transactions

No Available Data

Mark Leschly Mailing Address

Above is the net worth, insider trading, and ownership report for Mark Leschly. You might contact Mark Leschly via mailing address: Rho Capital Partners, Inc., 152 W 57th St 23rd Fl, New York Ny 10019.